联系方式

办公电话：(0773)2535678或3560088

电子邮箱：hliang@mailbox.gxnu.edu.cn

办公地址：桂林市七星区育才路15号：省部共建国家重点实验室1号楼302室

简介

梁宏，博士，教授。现任广西师范大学省部共建药用资源化学与药物分子工程国家重点实验室/教育部重点实验室主任，博士生导师；曾任广西师范大学校长（2002-2017），广西壮族自治区科协副主席，兼任南开大学、南京大学无机化学博士生导师和中南大学应用化学博士生导师（2001-2013）。先后主持国家自然科学基金重点项目1项、国家自然科学基金区域创新发展联合基金重点支持项目1项、973前期研究专项课题3项和国家自然科学基金项目10项；主持部省级级项目30余项。在PNAS，Nat. Commun., J. Am. Chem. Soc., Angew. Chem. Int. Ed., Adv. Sci.，ACSNano，Chem. Soc. Rev.，Coordin. Chem. Rev.，J. Med. Chem.，APSB和CCS Chem.等期刊发表SCI论文600余篇，并被SCI引用16600余次，H指数65；获授权中国发明专利80余项，欧洲发明专利1项；获得广西科学技术奖特别贡献奖、广西科技进步一等奖和广西自然科学一等奖等省级科技成果奖15项，广西优秀教学成果奖6项。2025年，作为带头人的“新型金属药物化学生物学研究团队”获广西创新争先团队奖。

主要研究方向

1．中药活性成分金属药物化学生物学

2．内源性蛋白质金属药物载运体系

3．诊疗一体化纳米医药材料

4．生命过程实时原位监测新方法

主要社会任职

英国皇家化学会会士（FRSC）（2015年）

中国化学会会士（FCCS）（2024年）

中国化学会理事（1998年起）

中国化学会无机化学学科委员会委员（1998年起）

中国化学会化学生物学学科委员会委员（2016年起）

中国药学会药物化学专业委员会委员（2024年起）

广西化学化工学会理事长（2001-2019）、荣誉理事长（2019年起）

国际期刊《Journal ofInorgnic Biochemistry》编委（2019-2012）

国际期刊《Journal ofNatural Medicines Research》编委

中国化学会期刊《无机化学学报》编委

中国化学会期刊《化学教育》编委

中国药学会期刊《中国药物化学杂志》编委

讲授课程

生物无机化学

主要代表性论文

1. Hui-Chao Lin†, Wen-Ying Shen†,Jian-Hua Wei†, Liu-Lin Chen, Chun-Peng Jia, Zu-Yu. Mo,Li-Xia Wang, Cheng Hou,Yang-Han Liu, Jihu Su, Hong Liang*, Zhen-Feng Chen*. Rhodium(III)-nitroxylradical complex triggers dual-pronged disulfidptosis-apoptosis in hepatocellularcarcinoma via metabolic sabotage and redox catalysis. Angewandte ChemieInternational Edition, 2026, 65, e17864.

2. Kun Yang, Qi-Yuan Yang, Kai-JieYang,Wu-Yan Yang, Juan Hou, Qian Chen,Yun-Qiong Gu, Muhammad Iqbal Choudhary,Hong Liang*, Zhen-Feng Chen*. Oxoaporphine-metformin Rhodium(III) mixed complexachieving dual antidiabetes and anticancer effects by interfering with glucose metabolismReprogramming. Journal of the American Chemical Society, 2025,147 (49), 45145-45156.

3. Yuan Lu†, Feng-Yang Wang†,Matthew S. Levine†, Hai-Rong Shi, Yuan Wang, Xiaolin Xiong, Liang-Mei Yang,Ya-Qian Shi, Taotao Zou*, Jonathan L. Sessler*, Hong Liang*, Ke-BinHuang*. Oxoisoaporphine alkaloid Iridium(III) derivative: an immunogenic cell deathinducer that engages the autophagy-dependent regulator cathepsin D. Journalof the American Chemical Society, 2025, 147, 15216-15228.

4. Haichao Liu*, Kai Tang, HaoZeng, Lijun Chen, Hong Liang*, Yanxing Jia*. Desymmetrization strategyin natural product total synthesis. Chemical Society Reviews, 2025,54, 6208-6237.

5. Hazrat Bilal, Sana Zahoor,Muhammad Iqbal Choudhary, Farzana Shaheen, Sukanya Dej-adisai, Hong Liang*,Zhen-Feng Chen*. Carboxylate embedded metal organic frameworks for potentialapplications in drug delivery and controlled release. CoordinationChemistry Reviews, 2025, 538, 216688-216717.

6. Xue-Yu Man, Zhen-Lei Zhang, HongLiang*, Feng Yang*. Single-molecular theranostic metal complexes:Integrating bio-imaging and cancer therapy. Coordination ChemistryReviews, 2025, 549, 217356-217392.

7. Yuan Lu†, Shan-Shan Wang†,Meng-Ya Li†, Rong Liu, Meng-Fan Zhu, Liang-Mei Yang, Feng-Yang Wang, Ke-BinHuang*, Hong Liang*. Cyclometalated iridium(III) complex based on isoquinolinealkaloid synergistically elicits the ICD response and IDO inhibition via autophagy-dependentferroptosis. Acta Pharmaceutica Sinica B, 2025, 15,424-437.

8. Ke-Bin Huang†*, Feng-Yang Wang†, Yuan Lu†, Liang-MeiYang, Nian Long, Shan-Shan Wang, Zhiying Xie, Matthew Levinec, Taotao Zou*,Jonathan L. Sessler*, Hong Liang*. Cu(II) complex that synergistically potentiatescytotoxicity and an antitumor immune response bytargeting cellular redoxhomeostasis. PNAS, 2024, 121(24), e2404668121.

9. Xueyu Man, Wenjuan Li, MinghuiZhu, Shanhe Li, Gang Xu, Zhenlei Zhang,  Hong Liang*, Feng Yang*. Anticancer tetranuclear Cu(I) complex catalyzes a clickreaction to synthesize a chemotherapeutic agent in situ to achieve targeted dual-agentcombination therapy for cancer. Angewandte Chemie International Edition,2024, 63, e202411846.

10. Peijing Xu†, Changchun Wen†,Cunji Gao*, Huihui Liu, Yingshu Li, Xiaolu Guo, Xing-Can Shen*, Hong Liang*. Near-infrared-II-activatableself-assembled manganese porphyrin-gold heterostructures for photoacoustic imaging-guidedsonodynamic-augmented photothermal/photodynamic therapy. ACS Nano,2024, 18, 713-727.

11. Yulong Bai†, Jing Hua†, JingjinZhao*, Shulong Wang, Mengjiao Huang, Yang Wang, Yanni Luo, Shulin Zhao*, Hong Liang*. A silver-induced absorptionred-shifted dual-targeted nanodiagnosis-treatment agent for NIR-II photoacousticimaging-guided photothermal and ROS simultaneously enhanced immune checkpoint blockadeantitumor therapy. Advance Science, 2024, 11, 2306375.

12. Qi-Yuan Yang†, RuiMa†, Yun-Qiong Gu†, Xiao-Fang Xu, Zhen-Feng Chen*, Hong Liang*. Arene-ruthenium(II)/osmium(II) complexes potentiate the anticancerefficacy of metformin via glucose metabolism reprogramming. Angewandte Chemie International Edition,2022, 61, e202208570.

13. XiaolinXiong†, Ke-Bin Huang†, Yuan Wang†, Bei Cao, YunliLuo, Huowen Chen, Yan Yang, Yan Long, Moyi Liu, Albert S.C. Chan, Hong Liang*, TaotaoZou*. Target profiling of an Iridium(III)-based immunogenic cell death inducer unveilsthe engagement of unfolded protein response regulator BiP. Journal of the American Chemical Society,2022, 144, 10407-10416.

14. Yan-Lei Ma†, Ji-Ping Yue†, Yao Zhang†, Chen-Zhang Shi†, MattOdenwald, Wenguang G. Liang, Qing Wei, Ajay Goel, Xue-Wen Gou, Jamie Zhang,Shao-Yu Chen, Wei-Jen Tang, Jerrold R. Turner, Feng Yang, Hong Liang*, Huan-Long Qin, Xiao-Yang Wu. ACF7 regulatesinflammatory colitis and intestinal wound response by orchestrating tightjunction dynamics. Nature Communications, 2017, 8,15375.

15. Ji-Ping Yue†, Yao Zhang†, Wen-Guang G. Liang, Xue-Wen Gou, PhilbertLee, Han Liu, Wan-Qing Lyu, Wei-Jen Tang, Shao-Yu Chen, Feng Yang*, Hong Liang*, Xiao-Yang Wu*. Invivo epidermal migration requires focal adhesion targeting of ACF7. Nature Communications,2016, 7, 11692.

16. Wenjuan Li, Shanhe Li,Zhenlei Zhang, Gang Xu, Xueyu Man, Feng Yang*, Hong Liang*. Developing a multitargetedanticancer palladium(II) agent based on the His-242 residue in the IIA subdomainof human serum albumin. Journal of Medicinal Chemistry, 2023, 66,8564-8579.

17. Xing Lu, Mei-Feng Wu, Jiang-LunWu, Hai-Qun Zhang, Hong Liang*,Zhen-Feng Chen*. Platinum-based Mcl‑1 inhibitor targeting mitochondria achievesenhanced antitumor activity as a single agent or in combination with ABT-199.Journal of Medicinal Chemistry, 2023, 66, 8705−8716.

18. Zhenlei Zhang†, Juzheng Zhang†,Tongfu Yang†, Shanhe Li, Gang Xu, HongLiang*, Feng Yang*. Developing an anticancer Platinum(II) compound based onthe uniqueness of human serum albumin. Journal of Medicinal Chemistry,2023, 66, 5669-5684.

19. Shuang Kan, Rong Li, Yanhui Tan, Fang Yang, Shaohua Xu, Lingzhu Wang,Lijun Zhang,Xuchen Sun, Xuanming Chen,Yuting Yang, Wei Shu, Huaibin Wan,Zheng-FengChen, Hong Liang*, Ming Chen*.Latexin deficiency attenuates adipocyte differentiation and protects miceagainst obesity and metabolic disorders induced by high-fat diet. Cell Death & Disease,2022, 13(2): 175 .

20. Wen-Ying Shen, Chun-PengJia, Li-Yi Liao, Liu-Lin Chen, Cheng Hou, Yang-Han Liu, Hong Liang*, Zhen-Feng Chen*. Copper(II) complexes of halogenated quinoline schiffbase derivatives enabled cancer therapy through glutathione-assisted chemodynamictherapy and inhibition of autophagy flux. Journal of Medicinal Chemistry, 2022, 65, 5134-5148.

21. Yi Gou, GuoJin Huang, JinlongLi, Feng Yang*, Hong Liang*. Versatile delivery systemsfor non-platinum metal-based anticancer therapeutic agents, Coordination Chemistry Reviews, 2021, 441, 213975.

22. Juzheng Zhang, Ming Jiang, Shanhe Li, Zhenlei Zhang, Hongbin Sun,Feng Yang*, Hong Liang*. Developing a novel anticancerGold(III) agent to integrate chemotherapy and immunotherapy. Journal of Medicinal Chemistry, 2021, 64, 6777-6791.

23. Ju-Zheng Zhang, Zhen-Lei Zhang, Ming Jiang, Shan-He Li, Hao-LiangYuan, Hong-Bin Sun, Feng Yang*, HongLiang*. Developing a novel gold(III) agent to treat glioma based on theunique properties of apoferritin nanoparticles: inducing lethal autophagy andapoptosis. Journal of Medicinal Chemistry, 2020, 63, 13695-13708.

24. Noor Shad Gul†, Taj-MalookKhan†, Yan-Cheng Liu, Muhammad Iqbal Choudhary, Zhen-Feng Chen*, Hong Liang*. Pd(II) and Rh(III) complexeswith isoquinoline derivatives induced mitochondria-mediated apoptotic and autophagiccell death in HepG2 cells, CCS Chemistry,2020, 2, 1626-1641.

25. Xing Lu, Yan-Cheng Liu, Chris Orvig, Hong Liang*, Zhen-Feng Chen*. Discovery of a copper-basedMcl‑1 inhibitor as an effective antitumor agent, Journalof Medicinal Chemistry, 2020, 63, 9154–9167.

26. Zhen-Lei Zhang, Ping Yu, YiGou, Ju-Zheng Zhang, Shan-He Li, Mei-Ling Cai, Hong-Bin Sun, Feng Yang*, HongLiang*. A novel brain-tumor-inhibiting copper(II) compound based onHSA–cell penetrating peptide conjugate. Journal of Medicinal Chemistry, 2019, 62, 10630–13069.

27. Ke-Bin Huang, Feng-Yang Wang, Xiao-Ming Tang, Hai-Wen Feng,Zhen-Feng Chen*, Yan-Cheng Liu, You-Nian Liu, Hong Liang*. Organometallic Gold(III) complexes similar to tetrahydroisoquinolineinduce ER-stress-mediated apoptosis and pro-death autophagy in A549 cancer cells. Journal of Medicinal Chemistry, 2018, 61, 3478-3490.

28. Zhen-Feng Chen*, Qi-Pin Qin, Jiao-Lan Qin, Jie Zhou, Yu-Lan Li, NanLi, Yan-Cheng Liu, Hong Liang*.Water-soluble ruthenium(II) complexes with chiral4-(2,3-Dihydroxypropyl)-formamide oxoaporphine (FOA): in vitro and in vivoanticancer activity by stabilization of G-Quadruplex DNA, inhibition of telomeraseactivity, and induction of tumor cell apoptosis. Journal ofMedicinal Chemistry, 2015, 58, 4771–4789.

29. Zhen-Feng Chen*, Qi-Pin Qin, Jiao-Lan Qin, Yan-Cheng Liu, Ke-BinHuang, Yu-Lan Li, Ting Meng, Guo-Hai Zhang, Yan Peng, Xu-Jian Luo, Hong Liang*.  Stabilization of G-quadruplex DNA,inhibition of telomerase activity, and tumor cell apoptosis byorganoplatinum(II) complexes with oxoisoaporphine. Journal of Medicinal Chemistry,2015, 58, 2159-2179.

30. Ming-Hua Zeng*,Min-Xia Yao, Hong Liang*, Wei-Xiong Zhang, Xiao-Ming Chen. A Single-molecule-magnetic, cubane-based, triangular Co12 supercluster.Angewandte Chemie International Edition, 2007, 46, 1832-1835.

近10年以来承担的主要科研项目

（1）国家自然科学基金区域创新发展联合基金-重点支持项目:广西道地药材活性成分金属配位优化及其肿瘤化学免疫治疗化学生物学研究（257万元）(2026-2029)

（2）国家自然科学基金-重点项目(21431001): 基于中药活性成分金属抗肿瘤配合物研究（360万元）(2015-2019)

（3）973计划专项课题：基于中药活性成分金属抗肿瘤配合物研究和天然环肽类潜药的化学组装与活性评价（255万元）（2012-2015）

（4）国家自然科学基金面上项目(22177022)：协同调控氧化(异)阿朴菲生物碱金属化合物的细胞毒活性与免疫激活响应研究 （60万元）(2022-2025)

（5）国家自然科学面上基金(21171043): 抗肿瘤先导植物药、金属基药物与人血清白蛋白相互作用研究（80万元） (2012-2015)

（6）教育部创新团队（学术带头人，排名第二）：天然活性物质的发现、结构改造与功能（450万元，2013-2016）（300万元，2017-2019滚动）

（7）广西院士后备人选培养工程项目：中药活性成分无机药物及其载运体系研究（1500万元） (2017-2022)

（8）广西重点研发计划项目：小龙虾细菌性疾病防治的广西中草药开发与关键技术研究（182万元）（2021-2023）

（9）广西自然科学基金项目（重点项目）：基于中药活性成分异喹啉类生物碱金属抗肿瘤配合物研究（100万元）（2013-2015）

（10）企业委托技术开发课题：珠海派锐尔新材料有限公司：对萘二甲酸的合成技术开发（250万元）（2024-2026）

主要荣誉称号

国家“万人计划”（百千万工程）领军人才（2016年）

广西院士后备人选培养工程首批人选（2016年）

中国科协“西部开发突出贡献奖”（2008年）

全国优秀科技工作者（2005年）

教育部第三届“高校青年教师奖”（2002年）

中国青年科技奖（2001年）

国家有突出贡献的中青年专家（1999年）

广西优秀专业技术人员（1999年）

“广西十百千人才工程”第一层次人选（1998年）

国家“百千万人才工程”首批人选（1996年）

国务院政府特殊津贴（1996年）

广西优秀专家（1996年）

版权所有 © 省部共建药用资源化学与药物分子工程国家重点实验室2008-2